中生製藥(01177.HK)治療惡性腫瘤藥獲上市批准
中國生物製藥(01177.HK)公布,由集團開發的依維莫司片已獲得國家藥品監督管理局的上市批准,是首個國內因「首仿獲批+首個挑戰專利成功」獲得12個月市場獨佔期的產品。
依維莫司為哺乳動物雷帕黴素靶蛋白(mTOR)的選擇性抑制劑,能通過干擾癌細胞的生長、分化和代謝,發揮抗腫瘤效應。該藥在腫瘤治療領域已經顯示出積極的作用,對多種惡性腫瘤的治療效果確切,其臨床價值得到充分肯定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.